![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CARDIOVASCULAR
-Adrenergic Receptors in the Effect of the
-Adrenergic Receptor Ligands, CGP 12177, Bupranolol, and SR 59230A, on the Contraction of Rat Intrapulmonary Artery
Institut National de la Santé et de la Recherche Médicale EMI-0356, Université Victor Segalen Bordeaux 2, Laboratoire de Pharmacologie de la Faculté de Pharmacie (V.L., F.P., B.M.) and Laboratoire de Physiologie Cellulaire Respiratoire (C.G., R.M.), Bordeaux, France; and Departament de Farmacologia, Facultat de Farmacia, Universitat de Valencia, Valencia, Spain (M.D.I.)
This study investigates the effect of the aryloxypropanolamines 4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimidazol-2-one (CGP 12177), bupranolol, and 3-(2-ethylphenoxy)-1[(1S)-1,2,3,4-tetrahydronaphth-1-ylamino]-(2S)-2-propanol oxalate (SR 59230A) [commonly used as
3- and/or atypical
-adrenergic receptors (
-AR) ligands] on the contractile function of rat intralobar pulmonary artery. Affinities of
-AR ligands for
1-adrenergic receptors (
1-AR) were also evaluated using [3H]prazosin binding competition experiments performed in rat cortical membranes. In intralobar pulmonary artery, CGP 12177 did not modify the basal tone, but antagonized the contraction induced by the
1-AR agonist phenylephrine (PHE). In arteries precontracted with PHE, CGP 12177 elicited relaxation, whereas in those precontracted with prostaglandin F2
(PGF2
), it further enhanced contraction. CGP 12177 induced an increase in intracellular calcium concentration in pressurized arteries loaded with Fura PE-3 and precontracted with PGF2
. In PGF2
precontracted arteries, phentolamine (an
-AR antagonist) and phenoxybenzamine (an irreversible
-AR antagonist) antagonized the contractile responses to PHE and CGP 12177. Both responses were also decreased by bupranolol and SR 59230A. Specific [3H]prazosin binding was displaced by CGP 12177, bupranolol, and SR 59230A with pKi values of 5.2, 5.7, and 6.6, respectively. In contrast, (±)-(R*,R*)-[4-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenoxy]acetic acid sodium (BRL 37344) and disodium 5-[(2R)-2-([(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino)propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL 316243) (nonaryloxypropanolamines
3-AR agonists) displayed very low affinity for [3H]prazosin binding sites (pKi values below 4). These data suggest that CGP 12177 exhibits partial agonist properties for
1-AR in rat pulmonary artery. They also show that bupranolol and SR 59230A exert an
1-AR antagonist effect. As a consequence, these aryloxypropanolamine compounds should be used with caution when investigating the role of
3- and atypical
-AR in the regulation of vascular tone.
Address correspondence to: Dr. Véronique Leblais, Laboratoire de Pharmacologie de la Faculté de Pharmacie, INSERM EMI-0356, Université Victor Segalen Bordeaux 2Casier 83, 146 rue Léo Saignat, 33076 Bordeaux cedex, France. E-mail: veronique.leblais{at}phcodyn.u-bordeaux2.fr
This article has been cited by other articles:
![]() |
V. Leblais, E. Delannoy, F. Fresquet, H. Begueret, N. Bellance, S. Banquet, C. Allieres, L. Leroux, C. Desgranges, A. Gadeau, et al. {beta}-adrenergic relaxation in pulmonary arteries: preservation of the endothelial nitric oxide-dependent {beta}2 component in pulmonary hypertension Cardiovasc Res, January 1, 2008; 77(1): 202 - 210. [Abstract] [Full Text] [PDF] |
||||